US 6,184,217 B2Granted

Use of K-252a derivative

AssigneeCephalon, Inc.

InventorsThomas M Engber, Forrest A. Haun, Michael S. Saporito, Lisa D. Aimone, Matthew S. Miller, Ernest Knight, Jr.

Life of this patent

Estimating the term…

Abstract

Disclosed herein are therapeutic methologies utilizing a ring substituted derivative of the indolocarbazole K-252a, the derivative represented by the formula:

Claims2

Dependent claims

A method for treating an inflammatory condition or disease comprising

administering to a host in need of such treatment a therapeutically effective amount of a compound represented by the formula

Dependencies are inferred from the claim text.

Facts

Application: 08/881,679Filed 24 Jun 1997 · us provisional application
Priority: 25 Jun 1996
Granted: 6 Feb 2001
Term ends: Not estimatedThe source records don’t support an estimate.

Classification25 codes

A61K 31/554
Having seven-membered rings, e.g. azelastine, pentylenetetrazole: having at least one nitrogen and one sulfur as ring hetero atoms, e.g.…
A61K 31/55
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/553
Having seven-membered rings, e.g. azelastine, pentylenetetrazole: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine,…
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…

Family

Application60/020,406Us provisional application · filed 25 Jun 1996
US 6,184,217 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results